Implantable scaffolds for treatment of sinusitis
This disclosure describes, inter alia, materials, devices, kits and methods that may be used to treat chronic sinusitis. An implant is configured to fit inside of the middle meatus of a human nasal cavity. The implant includes a therapeutic-agent formulation containing a layer of over 2000 micrograms of mometasone furoate. The implant releases the mometasone furoate for more than 12 weeks. A second implant can also be provided configured to fit inside the middle meatus. The second implant also includes a therapeutic-agent formulation containing a layer of over 2000 micrograms of mometasone furoate, and releases the mometasone furoate for more than 12 weeks.
1 . A combination therapy method of treating a sinus condition,
a) implanting first and second implants in a first and second middle meatus of a patient with a sinus condition but without a prior sinus surgery, wherein said patient has failed medical management based on the administration of oral and/or topical steroids and is a candidate for sinus surgery based on a SNOT score of symptoms, each implant comprising at least one coating containing over 2000 micrograms of mometasone furoate,
b) measuring a reduction in one or more symptoms, wherein after 24 weeks said patient is no longer a candidate for sinus surgery based on a SNOT score, thereby treating said sinus condition;
c) removing said first and second implants; and
d) measuring a further reduction in said symptoms one week post-removal based on a SNOT score.
2 . The therapy method of claim 1 , wherein said first and second implants are configured to release 20 to 80% of said mometasone furoate during the first 12 weeks of implantation.
3 . The therapy method of claim 1 , wherein said implanting is performed prior to surgery.
4 . The therapy method of claim 1 , wherein said implants exhibit a zero order release between 1 and 12 weeks after implantation.